The response rate exceeded the prespecified efficacy threshold and suggests epcoritamab may hold its own against Roche’s rival CD3xCD20 bispecific Lunsumio, which won FDA approval in follicular lymphoma last year.
Tag Archive for: Lunsumio
Versant Ventures-backed Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.
The U.S. health regulator has approved Roche Holding AG’s therapy for treating a type of rare cancer called follicular lymphoma.
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
